Engineering Metal‐Organic‐Framework‐Based STING Nanoagonists for PROTAC‐Enhanced Cancer Chemo‐Metalloimmunotherapy

to activate the stimulator of interferon genes (STING) pathway, cisplatin (CDDP) to induce nucleus DNA damage, and the bromodomain-containing protein 4 (BRD4) -targeting PROTAC dBET6 to promote mitochondrial DNA release and suppress PD-L1-mediated immune evasion. Coated with tumor cell membranes for homologous targeting and immune evasion, Mn-CDDP-dBET6@CM effectively induces cellular senescence, robust innate and adaptive immune activation, and tumor microenvironment remodeling. In vitro and in vivo studies demonstrate potent tumor growth inhibition, enhance dendritic cell maturation, and increase cytotoxic T cell infiltration. This nanoplatform offers a promising strategy to overcome chemoresistance and immunosuppression, providing a versatile approach for next-generation chemo-metalloimmunotherapy.